## Gene Summary
CYP51A1, also known as cytochrome P450 51A1, is a crucial enzyme in the biosynthesis of sterols. It is highly conserved across different species and catalyzes the demethylation of lanosterol to produce key sterol intermediates, a step that is pivotal for the synthesis of cholesterol in animals, ergosterol in fungi, and other essential sterols in plants. This gene is expressed in various tissues but is prominently active in the liver and intestines, reflecting its key role in cholesterol metabolism.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CYP51A1 is implicated in several crucial metabolic pathways, primarily focusing on cholesterol biosynthesis and homeostasis. The impact of CYP51A1 extends to various diseases linked with cholesterol metabolism, such as cardiovascular diseases and potentially some types of sterol-related congenital disorders. The enzyme encoded by CYP51A1 is targeted by antifungal drugs, specifically azoles, which inhibit its activity and thus sterol synthesis in fungi, making it important in the treatment of fungal infections.

## Pharmacogenetics
In pharmacogenetics, CYP51A1 holds particular significance in the context of its inhibition by azole drugs, which are used as antifungal agents. The effectiveness and safety of these drugs can vary based on genetic differences in the CYP51A1 gene among individuals. For instance, mutations in CYP51A1 can lead to altered enzyme activity, impacting drug efficacy and the risk of side effects. Thus, understanding genetic variations in CYP51A1 can assist in optimizing antifungal therapy, particularly in managing invasive fungal infections where resistance to azoles is a growing concern.